Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001193125-20-123045
Filing Date
2020-04-28
Accepted
2020-04-28 16:10:52
Documents
2

Document Format Files

Seq Description Document Type Size
1 424B5 d917355d424b5.htm 424B5 467274
2 GRAPHIC g917355g65y11.jpg GRAPHIC 52772
  Complete submission text file 0001193125-20-123045.txt   540968
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-228967 | Film No.: 20825103
SIC: 2834 Pharmaceutical Preparations